GAIN THERAPEUTICS INC (GANX)

US36269B1052 - Common Stock

1.57  +0.01 (+0.64%)

Fundamental Rating

1

GANX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. Both the profitability and financial health of GANX have multiple concerns. GANX does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GANX has reported negative net income.
GANX had a negative operating cash flow in the past year.
GANX had negative earnings in each of the past 5 years.
GANX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -148.74%, GANX is doing worse than 84.88% of the companies in the same industry.
GANX has a Return On Equity of -239.83%. This is in the lower half of the industry: GANX underperforms 70.46% of its industry peers.
Industry RankSector Rank
ROA -148.74%
ROE -239.83%
ROIC N/A
ROA(3y)-76.09%
ROA(5y)-119.48%
ROE(3y)-103.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

GANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
GANX has more shares outstanding than it did 1 year ago.
The debt/assets ratio for GANX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -7.25, we must say that GANX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.25, GANX is not doing good in the industry: 69.04% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.04 indicates that GANX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.04, GANX is not doing good in the industry: 60.68% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -7.25
ROIC/WACCN/A
WACC10.88%

2.3 Liquidity

GANX has a Current Ratio of 2.99. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
GANX has a worse Current ratio (2.99) than 65.12% of its industry peers.
GANX has a Quick Ratio of 2.99. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
GANX has a worse Quick ratio (2.99) than 62.63% of its industry peers.
Industry RankSector Rank
Current Ratio 2.99
Quick Ratio 2.99

More info and screens

3

3. Growth

3.1 Past

GANX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.36%, which is quite impressive.
GANX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
The Revenue has been growing by 22.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)35.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.05%
Revenue 1Y (TTM)-100%
Revenue growth 3Y22.52%
Revenue growth 5Y22.5%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -4.16% on average over the next years.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y43.65%
EPS Next 2Y23.84%
EPS Next 3Y9.32%
EPS Next 5Y-4.16%
Revenue Next Year-100%
Revenue Next 2Y-60.03%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GANX. In the last year negative earnings were reported.
Also next year GANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.84%
EPS Next 3Y9.32%

More info and screens

0

5. Dividend

5.1 Amount

GANX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GAIN THERAPEUTICS INC

NASDAQ:GANX (12/23/2024, 10:08:12 AM)

1.57

+0.01 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners11.92%
Inst Owner Change-31.31%
Ins Owners5.09%
Ins Owner Change20.09%
Market Cap40.76M
Analysts85.45
Price Target7.55 (380.89%)
Short Float %2.35%
Short Ratio1.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.7%
Min EPS beat(2)-105.88%
Max EPS beat(2)22.48%
EPS beat(4)2
Avg EPS beat(4)-16.64%
Min EPS beat(4)-105.88%
Max EPS beat(4)26.26%
EPS beat(8)3
Avg EPS beat(8)-19.26%
EPS beat(12)6
Avg EPS beat(12)-9.06%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.52%
PT rev (3m)0%
EPS NQ rev (1m)3.75%
EPS NQ rev (3m)25%
EPS NY rev (1m)6.57%
EPS NY rev (3m)6.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-75.31%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.57
P/tB 4.66
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -148.74%
ROE -239.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.09%
ROA(5y)-119.48%
ROE(3y)-103.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.99
Quick Ratio 2.99
Altman-Z -7.25
F-Score4
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)222.79%
Cap/Depr(5y)N/A
Cap/Sales(3y)56.6%
Cap/Sales(5y)52.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.05%
EPS Next Y43.65%
EPS Next 2Y23.84%
EPS Next 3Y9.32%
EPS Next 5Y-4.16%
Revenue 1Y (TTM)-100%
Revenue growth 3Y22.52%
Revenue growth 5Y22.5%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-60.03%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y4.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-40.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.09%
OCF growth 3YN/A
OCF growth 5YN/A